Camlin Fine Sciences informs about disclosure

17 May 2021 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations  2015  (SEBI  LODR  Regulations), Camlin Fine Sciences has informed that on  15th  May,  2021  the  Shares  Transfer/Administrative & Finance Committee (the Committee) of Camlin Fine Sciences (the  Company),  pursuant  to  the  powers  granted  by  the  Board  of  Directors,  has  approved  strategic  investment in AlgalR NutraPharms (AlgalR) by way of acquisition of equity shares amounting to 69.33% of the existing paid?up share capital (Secondary Purchase). The Committee has  also  approved  subscription  to  the  equity  shares  of  AlgalR  (Primary  Subscription).  Upon  consummation of the Secondary Purchase and Primary Subscription, the Company will hold 80% of the  paid?up capital of AlgalR on a fully diluted basis. The Company will now be executing the Investment  Agreement, Share Purchase Agreement and the incidental agreements / documents with AlgalR and  its promoters / other shareholders.  The details required under SEBI LODR Regulations are annexed.

The above information is a part of company’s filings submitted to BSE.

Camlin Fine Sciences Share Price

146.60 -1.75 (-1.18%)
01-Jan-2026 13:51 View Price Chart
Peers
Company Name CMP
BASF India 3920.00
Tata Chemicals 752.20
SRF 3054.90
Pidilite Inds. 1472.00
Deepak Nitrite 1706.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×